KDR and gastric cancer: Although Apatinib, a selective inhibitor of VEGFR2, has been approved by the FDA of the USA for the treatment of GC and confirmed to be a well effective treatment for gastric cancer patients [14], the molecular mechanism of Apatinib on the tumorigenesis of GC is still obscure.